Biocon's Malaysia Facility Receives OAI Status Post USFDA Inspection

Biocon's subsidiary, Biocon Sdn Bhd., is grappling with potential delays in product approvals after a recent United States Food and Drug Administration (USFDA) inspection at its insulin manufacturing facility in Johor, Malaysia.

Image Source -www.equitypandit.com

Biocon's subsidiary, Biocon Sdn Bhd., is grappling with potential delays in product approvals after a recent United States Food and Drug Administration (USFDA) inspection at its insulin manufacturing facility in Johor, Malaysia.

This facility received an Official Action Indicated (OAI) status, signifying the possibility of delayed approvals or supplements for its products, as announced in an official exchange filing by the company. The USFDA's concerns emerged during a Good Manufacturing Practices (cGMP) inspection carried out in July this year.

The regulatory scrutiny resulted in six observations related to drug substances, drug product units, and quality control laboratories. Additionally, two observations were noted for the delivery devices units, totaling eight observations in all. However, Biocon clarified that these observations mainly pertain to refining operational procedures and enhancing training programs, with no instances of systemic non-compliance or data integrity breaches detected.

In response to the inspection findings, Biocon promptly submitted a comprehensive Corrective and Preventive Action (CAPA) plan to the FDA. The company expressed confidence in its ability to execute the necessary actions as promised to address the concerns raised during the July inspection.

Also Read: Shreyas Shipping Delisting Attempt Falls Short, Shareholders Reject Counter Offer

Biocon also reassured stakeholders that the inspection outcomes would not significantly affect the manufacturing and distribution of the company's commercial products intended for the US market. While the news of the OAI status has had an impact on the stock market, with Biocon's shares declining by 4% in 2023, the company remains committed to resolving the issues highlighted by the USFDA.

In summary, Biocon's Malaysia facility is working diligently to overcome the challenges posed by the USFDA's inspection observations. The company's commitment to implementing corrective measures and maintaining the quality of its products underscores its dedication to ensuring continued operations in the US market.